Literature DB >> 21449232

Technical considerations in percutaneous hepatic perfusion--a multi-center experience.

Radcliffe A Antoine1.   

Abstract

Patients diagnosed with primary or metastatic liver cancer face a daunting future that is complicated by limited treatment options. Percutaneous hepatic perfusion is a novel approach to chemotherapy delivery that offers significant benefits over contemporary modalities. Percutaneous hepatic perfusion is a procedure in which a chemotherapeutic agent is administered at high doses via the hepatic artery where it perfuses the liver, is extracted and filtered using a veno-veno bypass circuit, a fenestrated multi-lumen double-balloon catheter, and two biocompatible hemoperfusion filters. Venous access is gained at the groin through the femoral vein after which the catheter is advanced and positioned in the inferior vena cava just below the right atrium.The catheter's proximal and distal balloons are inflated to occlude the inferior vena cava above and below the hepatic veins. The occlusion isolated the chemo-rich venous outflow of the liver from the systemic venous circulation. This maneuver also diverts venous blood returning to the heart from lower extremities of the azygos vein. Once the patient is on bypass, the agent is infused through the hepatic artery where it saturates the liver. The chemo-rich venous outflow is extracted through the double-balloon catheter by the bypass circuit. The blood is continuously filtered and cleared of the agent as it passes through the filters and returned to the patient through a catheter placed in the right internal jugular vein. A phase I study demonstrated efficacy with an overall radiographic response rate of 30% observed in treated patients. In 10 patients with ocular melanoma, a 50% overall response rate was observed, including two complete responses. The technique is minimally invasive and can be performed safely by a well-trained multi-disciplinary team. It offers significant benefits including multiple procedures without risks commonly associated with open abdominal surgery.

Entities:  

Mesh:

Year:  2011        PMID: 21449232      PMCID: PMC4680088     

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


  7 in total

1.  Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer.

Authors:  N Kemeny; M Gonen; D Sullivan; L Schwartz; F Benedetti; L Saltz; J Stockman; Y Fong; W Jarnagin; J Bertino; W Tong; P Paty
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

2.  Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies.

Authors:  James F Pingpank; Steven K Libutti; Richard Chang; Bradford J Wood; Ziv Neeman; Anthony W Kam; William D Figg; Souping Zhai; Tatiana Beresneva; Geoffrey D Seidel; H Richard Alexander
Journal:  J Clin Oncol       Date:  2005-05-20       Impact factor: 44.544

Review 3.  Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver.

Authors:  H R Alexander; D L Bartlett; S K Libutti
Journal:  Oncologist       Date:  2000

4.  Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.

Authors:  Mace L Rothenberg; Amit M Oza; Robert H Bigelow; Jordan D Berlin; John L Marshall; Ramesh K Ramanathan; Lowell L Hart; Sunil Gupta; Carlos A Garay; Brent G Burger; Nathalie Le Bail; Daniel G Haller
Journal:  J Clin Oncol       Date:  2003-06-01       Impact factor: 44.544

Review 5.  Epidemiologic aspects of uveal melanoma.

Authors:  K M Egan; J M Seddon; R J Glynn; E S Gragoudas; D M Albert
Journal:  Surv Ophthalmol       Date:  1988 Jan-Feb       Impact factor: 6.048

6.  Cancer statistics, 2003.

Authors:  Ahmedin Jemal; Taylor Murray; Alicia Samuels; Asma Ghafoor; Elizabeth Ward; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2003 Jan-Feb       Impact factor: 508.702

7.  Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors.

Authors:  T S Ravikumar; G Pizzorno; W Bodden; J Marsh; R Strair; J Pollack; R Hendler; J Hanna; E D'Andrea
Journal:  J Clin Oncol       Date:  1994-12       Impact factor: 44.544

  7 in total
  2 in total

Review 1.  Intra-arterial therapies for metastatic colorectal cancer.

Authors:  David S Wang; John D Louie; Daniel Y Sze
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

2.  Surgical resection plus biotherapy/chemotherapy improves survival of hepatic metastatic melanoma.

Authors:  Shun-Da Du; Yi-Lei Mao; Shao-Hua Li; Xin-Ting Sang; Xin Lu; Yi-Yao Xu; Hai-Feng Xu; Lin Zhao; Chun-Mei Bai; Shou-Xian Zhong; Jie-Fu Huang
Journal:  World J Hepatol       Date:  2012-11-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.